P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Contacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager


Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints


Recent Issues

December 2013

Features

Letter to the Editor

Inaccurate Serelaxin Chemical Structure

Antithrombin III Utilization in a Large Teaching Hospital

In a retrospective study to assess the use of antithrombin concentrates, the authors judged the plasma-derived product (Thrombate III) to be more cost-effective than the recombinant human form (ATryn) for patients with hereditary antithrombin deficiency.
Cristina M. Salas, PharmD; and Marta A. Miyares, PharmD, BCPS (AQ Cardiology)

Calculating the Dose of Subcutaneous Immunoglobulin for Primary Immunodeficiency Disease in Patients Switched From Intravenous to Subcutaneous Immunoglobulin Without the Use of a Dose-Adjustment Coefficient

Intravenous immunoglobulin (IVIG), a standard therapy for immune deficiency disorders, is not appropriate for all patients. As a result, a subcutaneous form (SCIG) has emerged as an alternative. The authors propose a tailored dosing approach for SCIG.
Michael Fadeyi, PharmD, MS; and Tin Tran, RPh

Meeting Highlights

American College of Rheumatology and Transcatheter Cardiovascular Therapeutics

Rheumatology topics included therapies for rheumatoid arthritis, psoriatic arthritis, and Behçet’s syndrome. At the TCT meeting, researchers examined the effects of pharmacological strategies for myocardial infarction, along with platelet function testing as a guide to antiplatelet therapy.
Walter Alexander

Dermatology Update

Advances in Psoriasis Treatment

Experts Comment on Recent Developments

Part 1 covers promising biologics that aim to promote safety and efficacy in treating psoriatic lesions. Part 2 addresses the problem of nonadherence to treatment.
Peter Sonnenreich, MA

Season’s Greetings

Thank You to Our 2013 Reviewers

Departments

Prescription: Washington

New FDA Medical Device Rule Imposes Minimal Burden on Hospitals

Facilities Able to Scan Unique Device Identifiers Will Benefit

New FDA rules on medical devices shouldn’t be a burden for hospitals that can scan unique device identifiers.
Stephen Barlas

Medication Errors

Building Patient-Safety Skills

Avoiding Pitfalls in Conducting a Root Cause Analysis

Matthew Grissinger, RPh, FASCP

Drug Forecast

Glucarpidase (Voraxaze), a Carboxypeptidase Enzyme for Methotrexate Toxicity

Glucarpidase (Voraxaze) for methotrexate toxicity
Mohammad A. Rattu, PharmD; Neal Shah, PharmD; Jessica M. Lee, PharmD; Antony Q. Pham, PharmD, BCPS; and Nino Marzella, BS, MS, PharmD

Pharmaceutical Approval Update

Duavee, an oral contraceptive; riociguat (Adempas) for two types of pulmonary hypertension; and macitentan (Opsumit) for pulmonary arterial hypertension
Marvin M. Goldenberg, PhD, RPh, MS

New Drugs/Drug News/New Medical Devices

FDA approvals, drug indications, and updates